109 related articles for article (PubMed ID: 15373969)
21. CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs.
Gray RC; Kuchtey J; Harding CV
J Leukoc Biol; 2007 Apr; 81(4):1075-85. PubMed ID: 17227820
[TBL] [Abstract][Full Text] [Related]
22. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
Li Y; Kandimalla ER; Yu D; Agrawal S
Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
[TBL] [Abstract][Full Text] [Related]
23. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
Nakano S; Morimoto S; Suzuki J; Nozawa K; Amano H; Tokano Y; Takasaki Y
Rheumatology (Oxford); 2008 Feb; 47(2):145-9. PubMed ID: 18160420
[TBL] [Abstract][Full Text] [Related]
24. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
[TBL] [Abstract][Full Text] [Related]
25. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
26. Chicken TLR21 acts as a functional homologue to mammalian TLR9 in the recognition of CpG oligodeoxynucleotides.
Brownlie R; Zhu J; Allan B; Mutwiri GK; Babiuk LA; Potter A; Griebel P
Mol Immunol; 2009 Sep; 46(15):3163-70. PubMed ID: 19573927
[TBL] [Abstract][Full Text] [Related]
27. Peptide conjugation at the 5'-end of oligodeoxynucleotides abrogates toll-like receptor 9-mediated immune stimulatory activity.
Putta MR; Zhu FG; Wang D; Bhagat L; Dai M; Kandimalla ER; Agrawal S
Bioconjug Chem; 2010 Jan; 21(1):39-45. PubMed ID: 20020767
[TBL] [Abstract][Full Text] [Related]
28. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
Senn JJ; Burel S; Henry SP
J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
[TBL] [Abstract][Full Text] [Related]
29. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of TLR9 activation.
Latz E; Visintin A; Espevik T; Golenbock DT
J Endotoxin Res; 2004; 10(6):406-12. PubMed ID: 15588423
[TBL] [Abstract][Full Text] [Related]
31. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
32. Decreased intracellular TLR9 confers hyporesponsiveness of RAW264.7 cells to subsequent CpG ODN challenge.
Wei L; Hong Z; Jiang Z; Guofu D; Hongwei C; Liangxi W; Yongling L; Bin L; Ping L
Int Immunopharmacol; 2006 Jun; 6(6):935-46. PubMed ID: 16644479
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
Ishii KJ; Gursel I; Gursel M; Klinman DM
Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
[TBL] [Abstract][Full Text] [Related]
34. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance.
Berghöfer B; Frommer T; König IR; Ziegler A; Chakraborty T; Bein G; Hackstein H
Clin Exp Allergy; 2005 Sep; 35(9):1147-54. PubMed ID: 16164440
[TBL] [Abstract][Full Text] [Related]
35. Activation of autoreactive B cells by CpG dsDNA.
Viglianti GA; Lau CM; Hanley TM; Miko BA; Shlomchik MJ; Marshak-Rothstein A
Immunity; 2003 Dec; 19(6):837-47. PubMed ID: 14670301
[TBL] [Abstract][Full Text] [Related]
36. Ligand-induced conformational changes allosterically activate Toll-like receptor 9.
Latz E; Verma A; Visintin A; Gong M; Sirois CM; Klein DC; Monks BG; McKnight CJ; Lamphier MS; Duprex WP; Espevik T; Golenbock DT
Nat Immunol; 2007 Jul; 8(7):772-9. PubMed ID: 17572678
[TBL] [Abstract][Full Text] [Related]
37. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets.
Linghua Z; Xingshan T; Fengzhen Z
Vaccine; 2008 Jan; 26(2):224-33. PubMed ID: 18063448
[TBL] [Abstract][Full Text] [Related]
38. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
[TBL] [Abstract][Full Text] [Related]
39. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
Yu D; Putta MR; Bhagat L; Li Y; Zhu F; Wang D; Tang JX; Kandimalla ER; Agrawal S
J Med Chem; 2007 Dec; 50(25):6411-8. PubMed ID: 17988082
[TBL] [Abstract][Full Text] [Related]
40. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens.
Andersen JM; Al-Khairy D; Ingalls RR
Biol Reprod; 2006 May; 74(5):824-31. PubMed ID: 16421230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]